about
Adrenal G protein-coupled receptor kinase-2 in regulation of sympathetic nervous system activity in heart failureRisk of acute myocardial infarction after transurethral resection of prostate in elderlyNew advances in beta-blocker therapy in heart failurecAMP-PKA-CaMKII signaling pathway is involved in aggravated cardiotoxicity during Fuzi and Beimu Combination Treatment of Experimental Pulmonary HypertensionThe role of G protein coupled receptor kinases in neurocardiovascular pathophysiologyStimulation of α1a adrenergic receptors induces cellular proliferation or antiproliferative hypertrophy dependent solely on agonist concentrationG protein-coupled Receptor Kinase 2 as a Therapeutic Target for Heart Failure.G protein βγ subunits regulate cardiomyocyte hypertrophy through a perinuclear Golgi phosphatidylinositol 4-phosphate hydrolysis pathway.A pharmacokinetic analysis of molecular cardiac surgery with recirculation mediated delivery of βARKct gene therapy: developing a quantitative definition of the therapeutic window.Myocardial β(2) -adrenoceptor gene delivery promotes coordinated cardiac adaptive remodelling and angiogenesis in heart failure.Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2) -adrenoceptor-catecholamine production axis in heart failureBiased β2-adrenoceptor signalling in heart failure: pathophysiology and drug discovery.Gene targeting in ischemic heart disease and failure: translational and clinical studies.Prognostic Value of Lymphocyte G Protein-Coupled Receptor Kinase-2 Protein Levels in Patients With Heart FailureImpact of diabetes on cardiac sympathetic innervation in patients with heart failure: a 123I meta-iodobenzylguanidine (123I MIBG) scintigraphic studyGRK 2 level in peripheral blood lymphocytes of elderly patients with acute myocardial infarctionCurrent and future G protein-coupled receptor signaling targets for heart failure therapyAdrenergic nervous system in heart failure: pathophysiology and therapy.GRK2 blockade with βARKct is essential for cardiac β2-adrenergic receptor signaling towards increased contractility.Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms.Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown.Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade.Synthetic biology with surgical precision: targeted reengineering of signaling proteins.Molecular targeting of Gα and Gβγ subunits: a potential approach for cancer therapeutics.Molecular aspects of the cardioprotective effect of exercise in the elderly.Physiology and pharmacology of the cardiovascular adrenergic system.Effects of exercise training on cardiovascular adrenergic system.Effects of physical activity on endothelial progenitor cells (EPCs)Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling.β1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapyMultiple functions of G protein-coupled receptor kinasesRole of G protein-coupled receptor kinase 2 in tumoral angiogenesis.Raf kinase inhibitor protein (RKIP) dimer formation controls its target switch from Raf1 to G protein-coupled receptor kinase (GRK) 2.Alterations of left ventricular deformation and cardiac sympathetic derangement in patients with systolic heart failure: a 3D speckle tracking echocardiography and cardiac ¹²³I-MIBG study.Conducting the G-protein Coupled Receptor (GPCR) Signaling Symphony in Cardiovascular Diseases: New Therapeutic ApproachesAngiotensin (1-7) induces MAS receptor internalization.Novel strategies for the treatment of heart failureCardiac G-protein-coupled receptor kinase 2 ablation induces a novel Ca2+ handling phenotype resistant to adverse alterations and remodeling after myocardial infarction.Parallel changes in neuronal AT1R and GRK5 expression following exercise training in heart failure.Angiotensin receptor blocker drugs and inhibition of adrenal beta-arrestin-1-dependent aldosterone production: Implications for heart failure therapy.
P2860
Q26785936-CA4D11AF-CAA4-409B-88E2-BCA0664BCD4EQ26859700-CF46FB1B-41DA-4AFE-A3DC-8A89C5E48EB1Q26865919-582AFF2B-23CE-4811-9A32-CB642FFEEEBFQ28822014-242D33D9-68FD-4D7B-A435-371733426C78Q30459130-9323A8DC-7AA5-4660-B5F5-F44238D51DB3Q31132937-8E8F4377-9F2C-4D69-889D-8FA0FD5449AAQ33604042-97ADB40D-15F4-4B30-9497-5FC2183FA315Q35171028-1F8E80B7-D136-4F27-904D-A89782969C3AQ36185039-A4E45AB3-D21A-4962-BF42-3CCB8C093F7CQ36252791-34F17A64-A1CF-4EE6-80F6-246A6AC04087Q36252811-3C8A271E-567D-4F73-865D-D99318481578Q36342091-861DD5CE-E4BF-4D1C-81B8-5D8261586275Q36617570-4A6CDE0C-24F9-425F-AB72-D98410246C96Q36757784-4873F7DC-2F42-4CB8-8BE2-4DBE67B79A5DQ37022630-859E0772-3317-44CD-9AEC-62816182D02EQ37229933-38C06709-63AC-4F1B-9E47-ECF99B0E6FB5Q37232104-04953983-58A3-4116-ADED-BFA1340C577FQ37349756-0B09243D-D411-486E-8FA7-5A416B0D86FBQ37356016-F830C6A7-DF7A-4A83-8659-BD5215AF6CD6Q37470858-8EDFAC1B-9F66-490F-9616-5DBDC0AAC0BEQ37981274-3C7BCA35-8EF0-4272-8990-5735E9E21114Q37984182-9834651D-23FB-4FA1-A67F-691824EDAA62Q38016028-BCF51778-E45F-4279-9A57-C267B1B5C0E9Q38096149-A56EB97F-EF12-4947-823A-899EFCBBA539Q38129354-7CD52E76-D460-4B57-B9E9-148D10992812Q38136643-DE97BD44-B17F-40FF-B037-B0386CA9BB61Q38172127-B7DAF453-5C1D-4871-8088-7C8ADD0B9AF4Q38189347-13E570C7-68C2-49C9-B3DE-740C715D5146Q38256143-316B4DB8-8407-4AAD-8E38-0D35716FE896Q38266154-2C204077-110E-4E1A-80D5-515F6E7DDA1CQ38599397-DD2D7FBA-E00F-41C4-8E75-70C027261214Q38866740-D528939C-BAD9-4FE8-A2B3-A3D194357B33Q39345564-806BD8F1-9D52-4D4B-B998-16E383B91087Q40968701-88FAF877-B046-4C66-A7DA-008A73D0A844Q41206403-FF260B56-379C-424B-9B14-DFF561AD4DA8Q41814772-7EDBBD1D-AD5D-475B-8FEB-E788F6ABB142Q41856322-0A5CB169-74B0-4A66-B69C-EFFAC8DC10E0Q41903724-29DEF61E-FD96-42CA-98CF-C1D3E60FED1FQ42258051-7382FAA3-56E7-4D05-9604-3A9950431647Q42371966-DCB77C3D-4E3E-4B42-9764-FA51F0947643
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
GRK2 as a novel gene therapy target in heart failure.
@en
GRK2 as a novel gene therapy target in heart failure.
@nl
type
label
GRK2 as a novel gene therapy target in heart failure.
@en
GRK2 as a novel gene therapy target in heart failure.
@nl
prefLabel
GRK2 as a novel gene therapy target in heart failure.
@en
GRK2 as a novel gene therapy target in heart failure.
@nl
P2860
P50
P1476
GRK2 as a novel gene therapy target in heart failure
@en
P2093
Walter J Koch
P2860
P304
P356
10.1016/J.YJMCC.2010.08.014
P577
2010-08-25T00:00:00Z